<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03846544</url>
  </required_header>
  <id_info>
    <org_study_id>58335</org_study_id>
    <nct_id>NCT03846544</nct_id>
  </id_info>
  <brief_title>Double Pick up in Poor Prognosis Women</brief_title>
  <acronym>DUOPICK</acronym>
  <official_title>Double Trigger and Ovum Retrieval vs. Conventional Antagonist Ovarian Stimulation Protocol in Poor Prognosis Women Undergoing IVF/ICSI: A Pilot Randomized Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>CRG UZ Brussel</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>CRG UZ Brussel</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this randomized pilot study is to compare the efficacy of double oocyte
      retrieval vs. conventional antagonist ovarian stimulation protocol in poor prognosis patients
      undergoing IVF/ICSI.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 1, 2019</start_date>
  <completion_date type="Anticipated">July 2021</completion_date>
  <primary_completion_date type="Anticipated">July 2021</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>number of oocytes retrieved (metaphase II oocytes) between the two arms</measure>
    <time_frame>1 month</time_frame>
    <description>number</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>number of preovulatory follicles</measure>
    <time_frame>1 month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>number of cumulus oocyte complexes (COCs) retrieved</measure>
    <time_frame>1 month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>number of oocytes fertilized</measure>
    <time_frame>1 month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>total number of available embryos</measure>
    <time_frame>1 month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>duration of ovarian stimulation</measure>
    <time_frame>1 month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>total dose of gonadotropins administered</measure>
    <time_frame>1 month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>clinical pregnancy rates</measure>
    <time_frame>4 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>live birth rates</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>cumulative live birth rates</measure>
    <time_frame>24 months</time_frame>
    <description>defined as the first live birth following the transfer of fresh and subsequent frozen-thawed embryos</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Follicular fluid (FF) and ii) cumulus cells (CC) analysis from each COC</measure>
    <time_frame>12 months</time_frame>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">46</enrollment>
  <condition>Fertility Disorders</condition>
  <arm_group>
    <arm_group_label>control group</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>double pick up group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CFA-double pick up</intervention_name>
    <description>In the study group, 225 IU of rFSH will continue after the first oocyte retrieval (OR). Antagonist administration will be initiated when at least one follicle measuring ≥14 mm will be present in the ultrasound. If one or more follicles ≥17 mm are observed, patients will undergo a second triggering with hCG 5000 IU and a second OR will be performed. In case of patients with no follicular development following 10 additional days of rFSH post-OR</description>
    <arm_group_label>double pick up group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age 25-40 years

          -  BMI ≤ 35 and ≥ 19

          -  Antimüllerian hormone (AMH) level of ≤1.5 ng/mL or antral follicular count of ≤6
             follicles or ≤5 oocytes retrieved in a previous cycle following standard conventional
             ovarian stimulation.

        Exclusion Criteria:

          -  Testicular sperm extraction

          -  History of &gt; 3 three consecutive previous unsuccessful IVF cycles

          -  BMI &gt;35 or &lt;19

          -  Use of oral contraceptives &lt;3 months before start of the treatment

          -  PCOS according to the Rotterdam criteria

          -  Ovarian stimulation for pre-implantation genetic testing (PGT-A/M)

          -  Medical/social freezing

          -  In vitro maturation (IVM)

          -  History of untreated autoimmune, endocrine or metabolic disorders,

          -  Ovarian cystectomy or oophorectomy
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>25 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Panagiotis Drakopoulos, Prof. Dr.</last_name>
    <phone>0032468180349</phone>
    <email>panagiotisdrakopoulos@hotmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Liese Boudry, Dr.</last_name>
    <email>Liese.Boudry@uzbrussel.be</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>UZ Brussel</name>
      <address>
        <city>Brussels</city>
        <state>Jette</state>
        <zip>1090</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Liese Boudry, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>February 15, 2019</study_first_submitted>
  <study_first_submitted_qc>February 18, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">February 19, 2019</study_first_posted>
  <last_update_submitted>January 24, 2020</last_update_submitted>
  <last_update_submitted_qc>January 24, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 27, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>CRG UZ Brussel</investigator_affiliation>
    <investigator_full_name>Panagiotis Drakopoulos</investigator_full_name>
    <investigator_title>Prof. Dr.</investigator_title>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

